Neuroblastoma is an aggressive childhood cancer with poor prognosis and limited therapeutic options. Here the authors report the results of a phase 2 trial of the anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma.
- Jaume Mora
- Godfrey C. F. Chan
- Brian H. Kushner
